🔎 Trials Near Me

Utama › Leukemia Mieloid Akut › Oregon

Kajian klinikal Leukemia Mieloid Akut di Oregon

27 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi di Oregon.

Bandar di Oregon

Teks kajian rasmi (Bahasa Inggeris)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • dan 7 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Providence Portland Medical Center, Portland
  • Providence Oncology and Hematology Care Clinic Westside, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • OHSU Knight Cancer Institute, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT03874052

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Mengambil pesertaFasa 3
6 Months – 21 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Oregon Health & Science University, Portland
Mengambil pesertaFasa 1/2
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

  • OHSU Knight Cancer Institute, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06504459

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • Oregon Health and Science University, Portland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT03471260

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Portland OR-OHSU, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Doernbecher Children's Hospital, Portland
Mengambil pesertaFasa 3
29 Days – 21 Years · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Willamette Valley Cancer Institute, Eugene
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07007312

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Jul 2026 · NCT05429632

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

  • OHSU Knight Cancer Institute, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT04659616

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

  • OHSU Knight Cancer Institute, Portland
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 13 Jul 2026 · NCT07228273

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Oregon Health and Science University, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07216443

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

  • OHSU Knight Cancer Institute, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Jul 2026 · NCT07548983

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Oregon Health & Science University/Doernbecher Children's Hospital, Portland
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

  • OHSU Knight Cancer Institute, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jun 2026 · NCT06357182

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Oregon Health and Science University, Portland
  • Oregon Oncology Specialists, Salem
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Apr 2026 · NCT04256317

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Oncology Associates of Oregon, Eugene
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 24 Mac 2026 · NCT04988555

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

  • OHSU, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Feb 2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • Oregon Health & Science University, Portland
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 hingga 120 · Semua jantina · Dikemas kini 25 Jul 2025 · NCT05237258

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.